Compared to other PARP1 inhibitors, talazoparib displays higher efficacy in reducing proliferation and inducing cell death in small cell lung cancer (SCLC) cell lines thanks to the parallel inhibition of PARP1 and PARP16, suggesting that the latter is an attractive therapeutic target for the treatment of different types of cancers (Fig. 5I) (Palve et al., 2022). This evidence concerns the gene PARP1 and cancer.